Arcturus Therapeutics Holdings, Inc. (ARCT)
15.19
-0.98
(-6.06%)
USD |
NASDAQ |
Aug 28, 16:00
15.18
-0.01
(-0.07%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Enterprise Value : 263.20M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 263.20M |
| August 27, 2026 | 291.05M |
| August 26, 2026 | 281.39M |
| August 25, 2026 | 270.30M |
| August 24, 2026 | 239.04M |
| August 21, 2026 | 213.74M |
| August 20, 2026 | 143.82M |
| August 19, 2026 | 123.64M |
| August 18, 2026 | 64.80M |
| August 17, 2026 | 62.81M |
| August 14, 2026 | 65.37M |
| August 13, 2026 | 54.85M |
| August 12, 2026 | 47.46M |
| August 11, 2026 | 45.19M |
| August 10, 2026 | 31.83M |
| August 07, 2026 | 42.06M |
| August 06, 2026 | 4.262M |
| August 05, 2026 | 9.378M |
| August 04, 2026 | 8.241M |
| August 03, 2026 | 1.988M |
| July 31, 2026 | -4.834M |
| July 30, 2026 | -0.2858M |
| July 29, 2026 | -3.981M |
| July 28, 2026 | -5.118M |
| July 27, 2026 | -4.834M |
| Date | Value |
|---|---|
| July 24, 2026 | -11.37M |
| July 23, 2026 | -3.981M |
| July 22, 2026 | -0.0016M |
| July 21, 2026 | 1.704M |
| July 20, 2026 | 1.135M |
| July 17, 2026 | 3.409M |
| July 16, 2026 | 7.104M |
| July 15, 2026 | 13.07M |
| July 14, 2026 | 12.50M |
| July 13, 2026 | 22.17M |
| July 10, 2026 | 29.56M |
| July 09, 2026 | 34.96M |
| July 08, 2026 | 38.94M |
| July 07, 2026 | 47.46M |
| July 06, 2026 | 40.36M |
| July 02, 2026 | 38.37M |
| July 01, 2026 | 27.28M |
| June 30, 2026 | 22.45M |
| June 29, 2026 | 6.457M |
| June 26, 2026 | 8.162M |
| June 25, 2026 | 6.457M |
| June 24, 2026 | 11.86M |
| June 23, 2026 | 13.85M |
| June 22, 2026 | 18.11M |
| June 18, 2026 | 26.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Exelixis, Inc. | 12.88B |
| PTC Therapeutics, Inc. | 4.308B |
| ACADIA Pharmaceuticals, Inc. | 4.128B |
| Alnylam Pharmaceuticals, Inc. | 31.39B |
| Anika Therapeutics, Inc. | 269.22M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.78M |
| Revenue (Quarterly) | 0.88M |
| Total Expenses (Quarterly) | 24.66M |
| EPS Diluted (Quarterly) | -0.8368 |
| Gross Profit Margin (Quarterly) | 31.82% |
| Profit Margin (Quarterly) | -2.70K% |
| Earnings Yield | -21.82% |
| Normalized Earnings Yield | -20.58 |